ATLANTA, GA — Despite promise for improving heart failure (HF) in pilot studies, an interatrial shunt (IAS) device did not meet the primary composite efficacy endpoint in a pivotal trial, a result ...

Madison Scientific, a Chicago-based startup developing a SmartShunt device, has raised $7 million in seed funding. The private medical device company said in a press release today that funding was ...

PHOENIX -- The functional and quality-of-life benefits of creating a left-to-right shunt in the interatrial septum to offload failing hearts held up over the midterm in a series of small feasibility ...

The US Food and Drug Administration (FDA) has granted Alleviant Medical an investigational device exemption (IDE), enabling the company to begin a pivotal trial evaluating its atrial shunt ...

10 patients enrolled with 100% implantation success Adona's adjustable interatrial shunt is designed so it can be modified post-implantation to provide a more adaptive and personalized lifetime ...

BOSTON, MA—This week’s Technology and Heart Failure Therapeutics (THT) 2023 meeting featured more than a dozen talks on interatrial shunts to reduce left atrial pressures and volume overload in heart ...

ATLANTA, GA—The implantation of a Ventura (V-Wave) interatrial shunt failed to improve prognosis or reduce symptoms across a wide range of patients with heart failure (HF), results from a new ...

The Centers for Medicare and Medicaid Services (CMS) has issued a new Healthcare Common Procedure Coding System (HCPCS) code and New Technology Ambulatory Payment Classification (New Technology APC) ...

Findings from an echocardiographic study of patients with heart failure with preserved or mildly reduced ejection fraction treated with an atrial shunt have shed more light on mechanisms that explain ...

For well-treated patients refractory to standard medications, the Ventura interatrial shunt was no better than sham in terms of primary effectiveness over nearly 2 years, defined by a hierarchical ...